These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An ephrin mimetic peptide that selectively targets the EphA2 receptor. Koolpe M; Dail M; Pasquale EB J Biol Chem; 2002 Dec; 277(49):46974-9. PubMed ID: 12351647 [TBL] [Abstract][Full Text] [Related]
4. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010 [TBL] [Abstract][Full Text] [Related]
5. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698 [TBL] [Abstract][Full Text] [Related]
6. Pinpointed Stimulation of EphA2 Receptors via DNA-Templated Oligovalence. Möser C; Lorenz JS; Sajfutdinow M; Smith DM Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404153 [TBL] [Abstract][Full Text] [Related]
7. Homing peptide-conjugated gold nanorods: the effect of amino acid sequence display on nanorod uptake and cellular proliferation. Alkilany AM; Boulos SP; Lohse SE; Thompson LB; Murphy CJ Bioconjug Chem; 2014 Jun; 25(6):1162-71. PubMed ID: 24892190 [TBL] [Abstract][Full Text] [Related]
8. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers. Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003 [TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030 [TBL] [Abstract][Full Text] [Related]
10. A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Singh DR; Pasquale EB; Hristova K Biochim Biophys Acta; 2016 Sep; 1860(9):1922-8. PubMed ID: 27281300 [TBL] [Abstract][Full Text] [Related]
11. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor. Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147 [TBL] [Abstract][Full Text] [Related]
12. YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells. Liu Z; Tao Z; Zhang Q; Wan S; Zhang F; Zhang Y; Wu G; Wang J Cancer Chemother Pharmacol; 2018 Apr; 81(4):687-695. PubMed ID: 29392452 [TBL] [Abstract][Full Text] [Related]
13. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists. Tognolini M; Incerti M; Pala D; Russo S; Castelli R; Hassan-Mohamed I; Giorgio C; Lodola A ChemMedChem; 2014 Jan; 9(1):67-72. PubMed ID: 24115725 [TBL] [Abstract][Full Text] [Related]
14. Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer. Efazat G; Novak M; Kaminskyy VO; De Petris L; Kanter L; Juntti T; Bergman P; Zhivotovsky B; Lewensohn R; Hååg P; Viktorsson K Oncotarget; 2016 Sep; 7(37):60332-60347. PubMed ID: 27533087 [TBL] [Abstract][Full Text] [Related]
15. Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer. Patel K; Doddapaneni R; Sekar V; Chowdhury N; Singh M Mol Pharm; 2016 Jun; 13(6):2049-58. PubMed ID: 27070720 [TBL] [Abstract][Full Text] [Related]
16. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction. Pala D; Castelli R; Incerti M; Russo S; Tognolini M; Giorgio C; Hassan-Mohamed I; Zanotti I; Vacondio F; Rivara S; Mor M; Lodola A J Chem Inf Model; 2014 Oct; 54(10):2621-6. PubMed ID: 25289483 [TBL] [Abstract][Full Text] [Related]
17. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515 [TBL] [Abstract][Full Text] [Related]
18. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Ogawa K; Pasqualini R; Lindberg RA; Kain R; Freeman AL; Pasquale EB Oncogene; 2000 Dec; 19(52):6043-52. PubMed ID: 11146556 [TBL] [Abstract][Full Text] [Related]
19. Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2. Baggio C; Udompholkul P; Gambini L; Pellecchia M J Med Chem; 2022 Nov; 65(22):15443-15456. PubMed ID: 36331527 [TBL] [Abstract][Full Text] [Related]
20. Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates. Udompholkul P; Baggio C; Gambini L; Sun Y; Zhao M; Hoffman RM; Pellecchia M Molecules; 2021 Jun; 26(12):. PubMed ID: 34204178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]